Capital keeps flowing into ASX Biotech shares in 2021

What is driving capital inflow into ASX biotech shares?

| More on:

Should you invest $1,000 in Mueller Industries, Inc. right now?

Before you buy Mueller Industries, Inc. shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mueller Industries, Inc. wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investor funds continue flowing into ASX listed biotechnology shares this year, with a total of almost $485 million of capital raised this year to date.

Adding the flurry of initial public offerings (IPO) undertaken in the biotech domain, one observes that this total increases to over $1 billion, according to today's Australian Financial Review.

Here, we examine just what is driving this recent trend in capital inflows towards ASX Biotech shares.

What is behind the surge in inflows to ASX Biotech shares this year?

There has been a spate of capital raised for ASX Biotech shares this year, such as Imugene Limited (ASX: IMU), Immutep Ltd (ASX: IMM) and Aroa Biosurgery Ltd (ASX: ARX).

For instance, Imugene recently "completed an upsized $95 million offer", issuing ~300 million additional shares at a price of 30 cents apiece.

Aroa also "banked $53 million in a placement and share purchase plan [SPP]" earlier this week to eligible investors at $1.165 per share. $5 million of this total is sought from the SPP.

There appears to be "four big reasons behind the recent flurry of [capital] raising" trends that have occurred this year.

These include the establishment of new equity-focused healthcare investment funds, outsized returns in the broad sector, and a cluster of collaborations with big pharmaceutical companies.

Moreover, it also appears the biotech sector "has the flavour of the month for investors", as per the Financial Review.

Bell Potter Securities analyst Darren Craike was quoted saying:

A lot of generalist funds are looking for alpha [above market return] in their portfolios…so many have started to gravitate to healthcare where there have been some exceptional returns in the last two to three years.

Moreover, the trends look set to continue for the time being, with a number of pre-IPO's on the cards.

To illustrate, Tissue Repair which is a regenerative medicine and aesthetic dermatology company, plans on "targeting a $25 million raise" via listing this year.

Additionally, upcoming biotech names Triad Lifesciences and Vitfrafy Lifesciences "are also confirmed to be pursuing listings" this year.

ASX Biotech shares snapshot

The basket of ASX Biotech shares contained within the S&P / ASX 200 Index (ASX: XJO) has provided a return of 116% since March of this year.

This select group has outpaced the overall broad index, which has posted a return of ~12.5% this year to date.

Such returns help to explain the attractiveness of ASX Biotech shares for Australian investors at the current standing.

More on Share Market News

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors were treated to a rare green session this Thursday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Broker Notes

Broker tips Woolworths shares to deliver a 20% return

Let's see what the broker is saying about this supermarket giant.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Earnings Results

2 ASX gambling shares making big moves on big news today

One of the ASX gambling stocks is soaring today while the other flounders. But why?

Read more »

A group of people in a corporate setting do a collective high five.
Earnings Results

This $9 billion ASX 200 healthcare share just rocketed 17%! Here's why

Investors are piling into this private hospital operator today.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Appen, IDP Education, Objective Corp, and Siteminder shares are tumbling today

These shares are having a tough time on Thursday. Let's find out why.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Share Gainers

Why Eagers, Medibank, Neuren, and Qantas shares are jumping today

These shares are having a strong session on Thursday. What's going on?

Read more »

carsales share price
Earnings Results

Guess which high-yielding ASX 200 stock just rocketed 22% on record revenue

Investors are sending the ASX 200 stock flying higher on Thursday. But why?

Read more »

Business woman watching stocks and trends while thinking
Share Market News

5 things to watch on the ASX 200 on Thursday

Here's what to expect on the Australian share market today as earnings season continues.

Read more »